A New FDA Approval Brings New Psychiatric Risks
The Carlat Psychiatry Podcast
00:00
SNRIs and Cyclobenzaprine: Evolving Psychiatric Treatments
This chapter explores the introduction and effects of SNRIs, particularly duloxetine and milnansaprine, highlighting their psychiatric applications and associated risks. It also examines the historical context and current prescription trends of cyclobenzaprine, noting its status as a leading off-label treatment for fibromyalgia.
Transcript
Play full episode
